Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20160476 | 0.89 | TSHR (0.34) | TSHR | |
| SCHEMBL2693754 | 0.86 | TSHR (0.50) | TSHRALDH1A1USP2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL2126410 | 0.85 | TSHR (0.53) | TSHRALDH1A1USP2CYP3A4CYP2D6 | |
| SCHEMBL20153271 | 0.84 | TSHR (0.36) | TSHR | |
| SCHEMBL18559577 | 0.82 | TSHR (0.37) | TSHRALDH1A1USP2CYP3A4CYP2D6 | |
| SCHEMBL30842407 | 0.79 | USP2 (0.31) | TSHRALDH1A1USP2CYP3A4CYP2D6 | |
| SCHEMBL21163920 | 0.78 | OPRM1 (0.35) | TSHR | |
| SCHEMBL20676135 | 0.78 | OPRM1 (0.35) | TSHR | |
| SCHEMBL21370481 | 0.78 | OPRM1 (0.35) | TSHR | |
| SCHEMBL21160923 | 0.78 | OPRM1 (0.35) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149401-A1 | FURIN INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | BP ASSET V, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-10723719-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190284172-A1 | Urea Derivatives and Uses Thereof | KALA BIO, Inc. | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149401-A1 | FURIN INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | FURIN, ACE, ACE2 | TSHR 4240/4885ALDH1A1 4423/4885USP2 1036/4885 |
| US-10723719-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | TSHR 857/4885ALDH1A1 1432/4885USP2 393/4885 |
| US-20190284172-A1 | Urea Derivatives and Uses Thereof | UACA, RB1, FLT1 | TSHR 857/4885ALDH1A1 1432/4885USP2 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.